2019 CRACK IT challenges: Transgene Track
The aim of this Challenge is to develop a non-invasive imaging approach to determine the in vivoefficacy and biodistribution of (chimeric antigen receptor) CAR-T cells and adeno-associated viruses (AAVs).
Phase 1: six months, Phase 2: Up to three years
Phase 1: Up to £100k, Phase 2: Up to £1 million
GSK and Novartis
Cell and gene therapies are emerging treatment modalities that offer new possibilities for the treatment of previously incurable conditions. They can be broadly categorised into two subsets: in vivo gene therapy, which involves the introduction of a therapeutic vector directly into the patient andex vivo gene therapy, which primarily uses haematopoietic cells to carry the transgenes of interest.
For more information, click here.